Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6350551 | 0.88 | PTGS2 (0.55) | PTGS2PTGS1EPHX2ABCB11ALDH1A1 | |
| SCHEMBL6343089 | 0.85 | PTGS2 (0.51) | PTGS2PTGS1EPHX2ABCB11ALDH1A1 | |
| SCHEMBL6013987 | 0.82 | PTGS2 (0.60) | PTGS2PTGS1EPHX2CA1CA2 | |
| SCHEMBL6013942 | 0.82 | PTGS2 (0.60) | PTGS2PTGS1EPHX2CA1CA2 | |
| SCHEMBL6351028 | 0.82 | PTGS2 (0.53) | PTGS2PTGS1EPHX2ABCB11ALDH1A1 | |
| SCHEMBL9116198 | 0.81 | NPC1 (0.47) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL6013977 | 0.81 | PTGS2 (0.61) | PTGS2PTGS1CA1CA2ABCB11 | |
| SCHEMBL6343151 | 0.80 | PTGS2 (0.48) | PTGS2PTGS1EPHX2ABCB11ALDH1A1 | |
| SCHEMBL8635859 | 0.79 | PTGS2 (0.41) | PTGS2PTGS1EPHX2CA1CA2 | |
| SCHEMBL6721395 | 0.77 | EPHX2 (0.38) | PTGS2PTGS1EPHX2ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | claimed |
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1146789-B1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2009-03-18 | — | — | EP | claimed |
| CN-1268614-C | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 2006-08-09 | — | — | CN | claimed |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | claimed |
| CN-1495170-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | G.D.ɪ����˾ | 2004-05-12 | — | — | CN | claimed |
| EP-0922697-B1 | Substituted Pyrazolyl benzenesulfonamides and their use as cyclooxygenase II inhibitors | SEARLE & CO (US) | 2003-02-26 | — | — | EP | claimed |
| US-6492411-B1 | TREATING ARTHRITIS; REDUCED SIDE EFFECTS | G. D. SEARLE & CO. | 2002-12-10 | — | — | US | claimed |
| EP-0923933-B1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | SEARLE & CO (US) | 2002-07-03 | — | — | EP | claimed |
| US-6413960-B1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS; ACTIVE IN REDUCING PROSTAGLANDIN-INDUCED PAIN AND SWELLING; ANALGESICS; ANTIPYRETICS; ARTHRITIS; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 2002-07-02 | — | — | US | claimed |
| US-6156781-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G. D. SEARLE & CO. (US) | 2000-12-05 | — | — | US | claimed |
| EP-0923933-A1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | G.D. SEARLE & CO. (US) | 1999-06-23 | — | — | EP | claimed |
| EP-0922697-A1 | Substituted Pyrazolyl benzenesulfonamides and their use as cyclooxygenase II inhibitors | G.D. SEARLE & CO. (US) | 1999-06-16 | — | — | EP | claimed |
| CN-1202828-A | Substituted pyrzolyl benzenesulfonanides for use in veterinary | SEARLE & CO (US) | 1998-12-23 | — | — | CN | claimed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | claimed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | claimed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | claimed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | PTGS2 279/4885PTGS1 539/4885EPHX2 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.